Breaking Down the TRAILBLAZER-ALZ 2 Trial
Psychopharmacology and Psychiatry Updates
00:00
Exploring Denanimab: Efficacy and Risks in Alzheimer's Treatment
This chapter explores the FDA approval of Denanimab, a monoclonal antibody aimed at slowing Alzheimer's progression by targeting beta amyloid plaques. It evaluates the TRAILBLAZER-2 trial findings, focusing on efficacy, risks, and the complexities of treatment implementation.
Transcript
Play full episode
